Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2019 Filed Feb 19, 2019 16:32 UTC |
Peters CameronVP of Finance
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011095 · doc4.xml · derivative · entry 2 Peters Cameron · CIK 0001765269 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 16:32 UTC |
Peters CameronVP of Finance
|
GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011095 · doc4.xml · derivative · entry 1 Peters Cameron · CIK 0001765269 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC |
Shacham SharonPresident & CSO
|
GrantRestricted Stock Units · Derivative | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 87,200 Underlying: Common Stock · 87,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC |
Shacham SharonPresident & CSO
|
GrantRestricted Stock Units · Derivative | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,200 Underlying: Common Stock · 87,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC |
Shacham SharonPresident & CSO
|
GrantStock Option (right to buy) · Derivative | 231,200 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 231,200 Underlying: Common Stock · 231,200 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC |
Shacham SharonPresident & CSO
|
GrantStock Option (right to buy) · Derivative | 231,200 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,200 Underlying: Common Stock · 231,200 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:23 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011077 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 87,200 Underlying: Common Stock · 87,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:23 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011077 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,200 Underlying: Common Stock · 87,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:23 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 231,200 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011077 · doc4.xml · derivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 231,200 Underlying: Common Stock · 231,200 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:23 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 231,200 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011077 · doc4.xml · derivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,200 Underlying: Common Stock · 231,200 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:30 UTC |
Varadan AnandEVP, Chief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 38,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011089 · doc4.xml · derivative · entry 2 Varadan Anand · CIK 0001650456 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:30 UTC |
Varadan AnandEVP, Chief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 102,800 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011089 · doc4.xml · derivative · entry 1 Varadan Anand · CIK 0001650456 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,800 Underlying: Common Stock · 102,800 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:29 UTC |
Primiano Christopher BrettEVP, CBO, GC & Secretary
|
GrantRestricted Stock Units · Derivative | 38,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011084 · doc4.xml · derivative · entry 2 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:29 UTC |
Primiano Christopher BrettEVP, CBO, GC & Secretary
|
GrantStock Option (right to buy) · Derivative | 102,800 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011084 · doc4.xml · derivative · entry 1 Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,800 Underlying: Common Stock · 102,800 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:27 UTC |
Frenkel RanChief Dev Operations Officer
|
GrantRestricted Stock Units · Derivative | 38,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011082 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:27 UTC |
Frenkel RanChief Dev Operations Officer
|
GrantStock Option (right to buy) · Derivative | 102,800 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011082 · doc4.xml · derivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,800 Underlying: Common Stock · 102,800 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:41 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-19-003066 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,357 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:41 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 12,500 | $10.23 | $127,823.75 |
DisclosureSEC source: 0001209191-19-003066 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.45, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:41 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-19-003066 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 743,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · balance_after: Reflects the transfer of 17,624 shares from the Sharon Shacham 2016 Qualified Annuity Interest Trust (the "Spouse's GRAT") to the spouse of the reporting person on December 10, 2018. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:37 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-19-003059 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,357 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:37 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 12,500 | $10.23 | $127,823.75 |
DisclosureSEC source: 0001209191-19-003059 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.45, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:37 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-19-003059 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Reflects the transfer of 17,624 shares from the Sharon Shacham 2016 Qualified Annuity Interest Trust (the "GRAT") to the reporting person on December 10, 2018. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:29 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-18-061769 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 27,857 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:29 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 12,500 | $10.11 | $126,422.50 |
DisclosureSEC source: 0001209191-18-061769 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.275, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:29 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-18-061769 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 726,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:28 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-18-061765 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,857 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:28 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 12,500 | $10.11 | $126,422.50 |
DisclosureSEC source: 0001209191-18-061765 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.275, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:28 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-18-061765 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:17 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-059988 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,061 Underlying: Common Stock · 9,600 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:17 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 9,600 | $11.00 | $105,600.00 |
DisclosureSEC source: 0001209191-18-059988 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:17 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 9,600 | $4.75 | $45,619.20 |
DisclosureSEC source: 0001209191-18-059988 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:20 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-059990 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 436,061 Underlying: Common Stock · 9,600 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:20 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 9,600 | $11.00 | $105,600.00 |
DisclosureSEC source: 0001209191-18-059990 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:20 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 9,600 | $4.75 | $45,619.20 |
DisclosureSEC source: 0001209191-18-059990 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 521,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 13:00 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-059620 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,661 Underlying: Common Stock · 400 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 13:00 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 400 | $11.14 | $4,454.52 |
DisclosureSEC source: 0001209191-18-059620 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.045 to $11.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 13:00 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 400 | $4.75 | $1,900.80 |
DisclosureSEC source: 0001209191-18-059620 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 13:03 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-059621 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 445,661 Underlying: Common Stock · 400 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 13:03 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 400 | $11.14 | $4,454.52 |
DisclosureSEC source: 0001209191-18-059621 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.045 to $11.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 13:03 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 400 | $4.75 | $1,900.80 |
DisclosureSEC source: 0001209191-18-059621 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:17 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-18-057950 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 40,357 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:17 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 12,500 | $11.65 | $145,592.50 |
DisclosureSEC source: 0001209191-18-057950 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.95, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:17 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-18-057950 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 726,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:16 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-18-057946 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,357 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:16 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 12,500 | $11.65 | $145,592.50 |
DisclosureSEC source: 0001209191-18-057946 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.95, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:16 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-18-057946 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:06 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-055828 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:06 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $12.63 | $126,304.00 |
DisclosureSEC source: 0001209191-18-055828 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.36 to $12.75, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:06 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-18-055828 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:09 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-055830 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 446,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.